Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.925
+0.065 (3.49%)
Jun 3, 2026, 3:42 PM EDT - Market open
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
322.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Invivyd | 55.87M |
| Fennec Pharmaceuticals | 51.00M |
| Artiva Biotherapeutics | 251.00K |
| InflaRx | 33.82K |
PALI News
- 7 days ago - Palisade Bio to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 21 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 21 days ago - Palisade Bio files $300M mixed securities shelf - TheFly
- 21 days ago - Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewsWire
- 22 days ago - Palisade Bio Registration statement: Registration filing - Filings
- 22 days ago - Palisade Bio Quarterly report: Q1 2026 - Filings
- 22 days ago - Palisade Bio Earnings release: Q1 2026 - Filings
- 4 weeks ago - Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis - GlobeNewsWire